Business Segment (Tables)

9 Months Ended

Sep. 30, 2023

Business Segment [Abstract]

Schedule of operations by business segment

Summarized below is information about the Company’s operations for the three and nine months ended September 30, 2023 and 2022 by business segment:

	Three Months Ended September 30,										Nine Months Ended September 30,
	Revenue				Earnings						Revenue				Earnings
	2023		2022		2023			2022			2023		2022		2023			2022
FOXO Labs	$	6	$	7	$	(269	)	$	(500	)	$	20	$	71	$	(873	)	$	(1,952	)
FOXO Life		4		7		(139	)		(1,158	)		15		22		(1,029	)		(3,070	)
		10		14		(408	)		(1,658	)		35		93		(1,902	)		(5,022	)
Impairment (a)						-			-							(2,633	)		-
Stock issuances (b)						-			-							(3,521	)		-
Corporate and other (c)						(3,104	)		(38,944	)						(13,671	)		(70,660	)
Interest expense						(148	)		(424	)						(865	)		(1,250	)
Total	$	10	$	14	$	(3,660	)	$	(41,026	)	$	35	$	93	$	(22,592	)	$	(76,932	)

(a) See Note 4 for additional information on the digital insurance platform, underwriting API, and longevity API impairment.

(b) Stock issuances includes the 2022 Bridge Debenture Release and the PIK Note Amendment. See Notes 5 and 7 for additional information.

(c) Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of ($1,312) and $3,866 as well as depreciation and amortization expense of $5 and $74 for the three months ended September 30, 2023 and 2022, respectively. Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of $2,582 and $5,556 as well as depreciation and amortization expense of $1,251 and $159 for the nine months ended September 30, 2023 and 2022, respectively. The three months ended September 30, 2023 and 2022 included ($36) and $31,010 for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. The nine months ended September 30, 2023 and 2022 also included ($244) and $55,493 for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. See Notes 4, 6, and 9 for additional information.